glp 1 pen DELIVERING ON GLP-1 DEMAND: A COMBINATION OF DEVICE OFFERINGS AND SUPPLY STRATEGY How GLP-1 Prescriptions are Reshaping
Description
Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder SocietyUnified Parkinsons Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinsons disease (15, 53)
Citius is encouraged by the constructive engagement with the FDA, Leonard Mazur, the companys chairman and CEO, said in a statement on Friday, adding that Citius plans to complete the remediation activities by the end of 2023 and file a resubmission early in 2024
Tirzepatide requires the same cold storage
The DCCT Research Group
10.1038/nature23910 124 KimS.-J.NianC.KarunakaranS.CleeS
